We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy
Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation
A new experimental Alzheimer’s drug called donanemab is generating major excitement as a potential breakthrough in treating the disease. In a large-scale clinical trial sponsored by pharmaceutical com
Read ArticleAmidst a burgeoning body of research, we're continually unravelling new facets of the versatile drug ketamine. A case in point is recent studies indicating another feather in ketamine's cap: treating
Lymphoma cancer is a type of cancer that affects the lymphatic system, which is responsible for fighting infections and diseases. While there are several types of lymphoma, the two main categories are
In the highly competitive world of pharmaceuticals, companies are constantly looking for the next big breakthrough drug. The quest for new treatments can be a risky and expensive endeavour, with no gu
It has been called "historic" that the first drug to slow the brain damage caused by Alzheimer's has been made. The scientific discovery puts a stop to decades of futility and demonstrates that new me
It is still attempting to resolve the fundamental issue. In general, Mark Cuban's new online pharmacy is delivering on its promises of offering low savings on hundreds of prescription medications. The
Subscribe to our weekly pharmaceutical intelligence digest